BR112015011430A2 - composição para liberação imediata e prolongada - Google Patents

composição para liberação imediata e prolongada

Info

Publication number
BR112015011430A2
BR112015011430A2 BR112015011430A BR112015011430A BR112015011430A2 BR 112015011430 A2 BR112015011430 A2 BR 112015011430A2 BR 112015011430 A BR112015011430 A BR 112015011430A BR 112015011430 A BR112015011430 A BR 112015011430A BR 112015011430 A2 BR112015011430 A2 BR 112015011430A2
Authority
BR
Brazil
Prior art keywords
immediate
composition
prolonged release
release
active ingredient
Prior art date
Application number
BR112015011430A
Other languages
English (en)
Portuguese (pt)
Inventor
Vilasrao Somwanshi Amol
Hagsten Arne
Wannerberger Kristin
Verma Rajan
Boorugu Rambabu
Vinayakrao Barabde Umesh
Ahuja Varinder
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of BR112015011430A2 publication Critical patent/BR112015011430A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/095Oxytocins; Vasopressins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112015011430A 2012-11-21 2013-11-21 composição para liberação imediata e prolongada BR112015011430A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3575DE2012 2012-11-21
IN3947DE2012 2012-12-20
PCT/EP2013/074373 WO2014079922A1 (en) 2012-11-21 2013-11-21 Composition for immediate and extended release

Publications (1)

Publication Number Publication Date
BR112015011430A2 true BR112015011430A2 (pt) 2017-07-11

Family

ID=49619947

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015011430A BR112015011430A2 (pt) 2012-11-21 2013-11-21 composição para liberação imediata e prolongada

Country Status (18)

Country Link
EP (1) EP2922525A1 (enrdf_load_stackoverflow)
JP (1) JP2016500088A (enrdf_load_stackoverflow)
KR (1) KR20150085826A (enrdf_load_stackoverflow)
CN (1) CN104797240A (enrdf_load_stackoverflow)
AR (1) AR093585A1 (enrdf_load_stackoverflow)
AU (1) AU2013349682A1 (enrdf_load_stackoverflow)
BR (1) BR112015011430A2 (enrdf_load_stackoverflow)
CA (1) CA2891365A1 (enrdf_load_stackoverflow)
EA (1) EA201590805A1 (enrdf_load_stackoverflow)
HK (1) HK1213779A1 (enrdf_load_stackoverflow)
IL (1) IL238648A0 (enrdf_load_stackoverflow)
IN (1) IN2015DN03984A (enrdf_load_stackoverflow)
MX (1) MX2015006399A (enrdf_load_stackoverflow)
PH (1) PH12015501096A1 (enrdf_load_stackoverflow)
SG (2) SG10201703388TA (enrdf_load_stackoverflow)
TW (1) TW201422254A (enrdf_load_stackoverflow)
WO (1) WO2014079922A1 (enrdf_load_stackoverflow)
ZA (1) ZA201503603B (enrdf_load_stackoverflow)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016525548A (ja) 2013-07-23 2016-08-25 アラーガン、インコーポレイテッドAllergan,I� Β−3アドレナリン受容体刺激薬と組み合わせたデスモプレシンを含む方法及び組成物
KR20150144209A (ko) * 2014-06-16 2015-12-24 훼링 비.브이. 안정화된 데스모프레신 또는 이의 약학적으로 허용가능한 염을 함유 약학 조성물
CN106999538A (zh) * 2014-11-20 2017-08-01 阿勒根公司 包含去氨加压素与α‑肾上腺素能受体拮抗剂组合的方法和组合物
WO2016114812A1 (en) * 2015-01-12 2016-07-21 Robert Niichel Layered sustained-release microbeads and methods of making the same
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
CN108135870A (zh) * 2015-09-01 2018-06-08 韦尔斯利医药有限公司 延缓、延迟和立即释放型制剂及其制造方法和用途
WO2017058428A1 (en) * 2015-09-30 2017-04-06 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
AU2016331879A1 (en) * 2015-09-30 2018-05-17 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
TW201726114A (zh) * 2015-11-23 2017-08-01 魏斯理製藥公司 降低排尿頻率之組成物、其製備方法、及其應用
CN108601782A (zh) * 2015-12-18 2018-09-28 韦尔斯利医药有限公司 用于缓解尿频的组合物,其制备方法和用途
KR20220100077A (ko) 2016-04-21 2022-07-14 발큐리아 에이비 암의 예비치료용 조성물 및 방법
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
KR20190104322A (ko) * 2017-01-11 2019-09-09 훼링 비.브이. 속붕해성 약학적 조성물
KR20190021180A (ko) * 2017-08-22 2019-03-05 아주대학교산학협력단 퇴행성 신경질환 치료용 복합 제형 조성물
US12389928B1 (en) * 2024-10-25 2025-08-19 Mccormick & Company, Inc. Flavor-changing product

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003184A1 (en) 1996-07-19 1998-01-29 Clarke-Garegg, Margaret, A. Levan derivatives, their preparation, composition and applications including medical and food applications
SE9803871D0 (sv) 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
NZ535861A (en) * 2002-05-07 2006-11-30 Ferring Bv Desmopressin acetate in an orodispersible dosage form that disintegrates in the mouth within 10 seconds
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
CN100366294C (zh) 2004-04-30 2008-02-06 量子高科(北京)研究院有限公司 一种口腔速溶制剂及其生产方法
EP1629834A1 (en) 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
WO2007029087A2 (en) 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Controlled release multiple unit formulations
US20090192228A1 (en) 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
CN102245171A (zh) * 2008-11-10 2011-11-16 株式会社爱茉莉太平洋 缓释微粒及其制备方法
WO2011013082A1 (en) * 2009-07-31 2011-02-03 Ranbaxy Laboratories Limited Multi-layered, multiple unit pharmaceutical compositions
JO3112B1 (ar) * 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
AU2011234637B2 (en) * 2010-03-29 2013-08-29 Ferring B.V. A fast dissolving pharmaceutical composition
MX356601B (es) * 2010-03-30 2018-05-29 Productos Maver S A De C V Combinación farmacéutica con efecto antimigrañoso, en presentación sólida de liberación diferenciada.
US20120135050A1 (en) * 2010-07-08 2012-05-31 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof

Also Published As

Publication number Publication date
IL238648A0 (en) 2015-06-30
JP2016500088A (ja) 2016-01-07
WO2014079922A1 (en) 2014-05-30
EA201590805A1 (ru) 2015-11-30
CN104797240A (zh) 2015-07-22
PH12015501096A1 (en) 2015-07-27
SG10201703388TA (en) 2017-05-30
IN2015DN03984A (enrdf_load_stackoverflow) 2015-10-02
CA2891365A1 (en) 2014-05-30
AU2013349682A1 (en) 2015-06-04
SG11201503913TA (en) 2015-06-29
EP2922525A1 (en) 2015-09-30
MX2015006399A (es) 2015-07-21
TW201422254A (zh) 2014-06-16
KR20150085826A (ko) 2015-07-24
HK1213779A1 (zh) 2016-07-15
AR093585A1 (es) 2015-06-10
ZA201503603B (en) 2016-01-27

Similar Documents

Publication Publication Date Title
BR112015011430A2 (pt) composição para liberação imediata e prolongada
BR112015022972A2 (pt) composição farmacêutica de cloridrato de s-cetamina
BR112013031268A8 (pt) polipeptídeos
MX2015008628A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
BR112015000578A2 (pt) moduladores da via do complemento e usos dos mesmos
PE20151067A1 (es) Inhibidores de autotaxina
PE20150092A1 (es) Composiciones farmaceuticas que contienen fumarato de dimetilo
EA201690102A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
MX2013003365A (es) Composicion farmaceutica.
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
CL2012001836A1 (es) Compuestos de pirazol, antagonista de crth2; composicion farmacéutica; uso en el tratamiento de trastornos inflamatorios, infecciosos, inmunoreguladores, enfermedades respiratorias, gastrointestinales o dolencias, entre otros.
BR112012024673A2 (pt) composição anestésica termogelificante
BR112013008601A8 (pt) Formulações de emulsão de clevidipina contendo agentes antimicrobianos
CL2014003503A1 (es) Composición farmacéutica para uso intramamario que comprende un ácido fosfónico y al menos un agente antimicrobiano; y uso para el tratamiento o prevención de mastitis en mamífero no humano.
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias
PE20150353A1 (es) Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, metodos para su preparacion, preparaciones farmaceuticas que los contienen, asi como su uso para la preparacion de medicamentos
BR112014032759A2 (pt) composições lipídicas de racecadotril
BR112015023387A2 (pt) composições lipídicas de racecodotril
BR112013024824A2 (pt) ésteres isopentílicos para uso em composições cosméticas, dermatológicas ou farmacêuticas
CU24163B1 (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
CL2016001094A1 (es) Silicato de zirconio microporoso para el tratamiento de hipercalemia.
MX2016000294A (es) Composicion farmaceutica para liberacion sostenida de lanreotida.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements